Iomeron (Iomeprol)

Iomeprol contains iodine atoms with a high atomic number, which absorb X‑rays more effectively than surrounding tissues. After injection, it distributes in the extracellular fluid, increasing radiodensity of the targeted area. This contrast difference allows imaging systems to produce detailed pictures of vascular, joint and cerebrospinal fluid structures.

The dose of Iomeron is individualized by the prescribing physician based on the specific imaging study, patient weight, renal function and the required level of contrast enhancement. Dosage calculations follow established radiology guidelines and are adjusted to achieve optimal image quality while minimizing exposure.

The safety of Iomeron in pregnancy and lactation has not been definitively established. Because iodinated contrast agents cross the placenta and may be secreted in breast milk, it should only be used when clearly needed and after careful risk‑benefit assessment by the healthcare provider.

To order Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and assistance with import documentation.

Iomeron is a non‑ionic, low‑osmolality iodinated contrast medium, which generally offers a lower incidence of adverse reactions compared with older high‑osmolality agents. Its physicochemical profile provides strong X‑ray attenuation and good tolerability, making it comparable to other modern agents such as iohexol or iopamidol for similar imaging indications.

Store Iomeron at ambient temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light, moisture and extreme temperature fluctuations. Do not freeze the solution, and inspect the container for any signs of damage before use.

Iomeron is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via intra‑arterial, intra‑articular or intrathecal routes, depending on the imaging study. The injection is performed under aseptic technique, and the volume is determined by the specific diagnostic protocol.

Serious risks include severe allergic reactions such as anaphylaxis, acute renal impairment (contrast‑induced nephropathy), significant hypotension or cardiovascular collapse, and pulmonary edema. Patients with known iodine allergy, compromised kidney function or severe cardiac disease should be closely monitored, and emergency measures must be readily available.

Iomeron should be avoided in patients with a documented severe hypersensitivity to iodinated contrast media, uncontrolled asthma, active renal failure (eGFR < 30 mL/min/1.73 m²), or in those who have experienced prior anaphylactic reactions to similar agents. The prescribing clinician must evaluate each case individually.